**Biotech Investors Concerned About Effects of NIH Research Cuts** Investors in the biotech industry are worried about the potential negative impact of funding cuts to the National Institutes of Health (NIH). These cuts could slow down important scientific research and development of new treatments, creating an atmosphere of fear and uncertainty. Medications like Humira and Keytruda, which were developed with the help of NIH-funded research, might face challenges in the future if similar research is affected by these budget reductions.
Investors have warned that the Trump administration’s plans to cut funding for the National Institutes of Health (NIH) could negatively impact the U.S. drug industry in the long run. These cuts might slow down the development of new medications, such as those used for treating conditions like high blood pressure or diabetes.